Skip to main content

Table 4 Distribution of AS on all modalities

From: Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?

AS

WBMRI

CT

FDG-PET/CT

BS

WBMRI & CT

WBMRI & FDG-PET/CT

WBMRI & BS

Bone only

16

0

0

1

1

0

1

Bone and viscera/soft tissues

4

0

0

N/A

0

0

N/A

Viscera/soft tissues only

24

Liver

17

Lymph nodes

1

Lungs

1

N/A

0

Retroperitoneal

1

N/A

Lymph nodes

3

Peritoneal

2

Liver and peritoneal

2